

I'm Asahi, General Manager, Corporate Headquarters of USHIO INC.

Based on the financial results disclosed on our website today, I would like to explain the details of our financial results for first quarter FY2024.

Please refer to the slide on page two.

Q1 FY2023 Overview	USHIO
1 O1 EV2022 lower revenues and earnings as planned	
1. Q1 FY2023 lower revenues and earnings as planned	
 2. FY2023 Forecast remain as announced on May 11, 2 3. Deporting cogmonte changed as of 01 EV2022 	023
3. Reporting segments changed as of Q1 FY2023	

Today, we will discuss the three main items listed.

The Q1 results were affected by deteriorating market conditions for semiconductors and flat panel displays, resulting in lower sales and profits compared to the same period last year, but the effects have already been factored in, and we are on track with respect to our full year earnings forecast. Therefore, there is no change in the full year forecast for FY2023.

In addition, the Company has changed its reportable segments from this fiscal year.

I would like to explain our financial results for Q1. Please move on to page four.

T Financial Deculta far 01 5V2022	
I. Financial Results for Q1 FY2023	
II. Full-Year Forecast for FY2023	
III. Supplementary Information	

Financial Results for	Q1 FY2023	USHIO
Net Sales 39.2 billion yen	 YoY Comparison: -0.4 billion yen (-1.1%) Industrial Processed Business: Sales decreased due to se market condition and FPD market deteriorating Visual Imaging Business: Sales increased on progress in management(SCM) reform and resolving parts shortage projectors, and owing to a lower yen 	supply chain
EBITDA* 3.9 billion yen	 YoY Comparison: -2.3 billion yen (-37.4%) Impact of net sales decrease Expanding in strategic investments in R&D and human response of the sales of	esources
Profit Attribute to Owners of Parent 1.7 billion yen	YoY Comparison: -2.0 billion yen (-53.5%) Non-operating Income - Forex gain and loss: -0.0 billion yen (Q1 FY2022: 1.	0 billion yen)

This is the summary of the results for Q1.

The sales decreased by 1.1% to JPY39.2 billion. In the previous fiscal year, demand for semiconductors and LCD panels remained at a high level, but market conditions subsequently deteriorated. The trend of capital investment being pushed back increased, and capacity utilization also declined, resulting in declined sales of UV lamps. In addition, sales of large field steppers for cutting-edge IC package substrates were in a temporary adjustment phase due to changes in market conditions, and in addition, sales are biased toward H2 of this fiscal year, resulting in a decline in overall sales in the industrial process business.

On the other hand, visual imaging equipment, which was strongly affected by the shortage of parts and materials in the previous fiscal year, is on a recovery trend, and the ongoing supply chain management reform is progressing smoothly.

Profit attributable to owners of the parent decreased 37.4% to JPY3.9 billion. In addition to lower sales in the industrial process business, the decrease in profit was due to increased strategic investments in R&D and human resources for the future.


Net income for the quarter decreased by 53.5% to JPY1.7 billion due to the decrease in operating income and the fact that JPY1 billion foreign exchange gain recorded in non-operating income and expenses in the previous period did not occur during this period.

Please see the slide on page six for a step chart of the details of the change in EBITDA.

Summary of Financial Results

USHIO

		Q1 FY2022	Q1 FY2023	YoY com	iparison
(E	illions of yen)	L	X	Changes	%
Net Sales		39.7	39.2	-0.4	(1.1)%
Operating Prof	it*1	4.4	2.0	-2.4	(54.1)%
Operating Margin*	1	11.3%	5.2%	(6.0)P	-
EBITDA*2		6.3	3.9	-2.3	(37.4)%
EBITDA Margin		15.9%	10.1%	(5.8)P	-
Ordinary Profit		6.2	2.8	-3.4	(55.1)%
Profit Attributable to Owner of Parent		3.8	1.7	-2.0	(53.5)%
EPS (yen)		32.18	15.36	-16.82	(52.3)%
EOREX (von)	USD	126	136	+10	-
FOREX (yen)	EUR	137	148	+11	-




I will explain the main breakdown of the JPY2.3 billion decrease in EBITDA.

Income increased by JPY0.2 billion due to the depreciation of the yen. Regarding businesses, in the industrial process business, the net income declined by JPY0.9 billion due to the deteriorating semiconductor market conditions. Regarding nonbusiness aspects, a total of JPY1.3 billion was allocated for increased strategic investments, including R&D and human resource investments for the future.

The JPY0.9 billion increase in investment in human resources includes the introduction of a stock grant program for employees and an increase in personnel related to an acquisition project at affiliated companies.

Next, I will explain the business results by segment. Please look at page seven.



Before I explain our business performance by segment, I would like to remind you that we have changed our reportable segments for this fiscal year. The relationship to the former segments is as shown.

Also, please refer to slides 25 and 26 of this presentation later to see how the new and old sub-segments relate to each other.

I will now explain from the next page based on the new reporting segments.

Please see the slide on page eight.

1 FY2023 Finan	cial Results by	Dusiness Seyi	nents			
		O1 FY2022	Q1 FY2023	YoY Com	parison	
	(Billions of yen)	Q1112022	Q1112025	Changes	(%)	
	Net Sales	19.8	17.4	-2.3	(12.1)%	
Industrial Processes	Operating Profit (Operating Margin)	3.9 (19.8%)	2.2 (12.9%)	-1.6 ((7.0)P)	(42.9)%	
	Net Sales	15.5	17.6	+2.0	+13.2%	
Visual Imaging	Operating Profit (Operating Margin)	1.2 (7.8%)	0.6 (3.5%)	-0.5 ((4.2)P)	(48.4)%	
Life Sciences	Net Sales	1.4	1.3	-0.0	(4.0)%	
	Operating Profit (Operating Margin)	- 0.6 ((47.5)%)	-0.4 ((32.7)%)	+0.2 (+14.7P)	-	
	Net Sales	2.3	2.5	+0.1	+6.6%	
Visual Imaging	Operating Profit (Operating Margin)	0.1 (6.1%)	-0.3 ((12.9)%)	-0.4 ((19.0)P)	-	
	Net Sales	0.4	0.2	-0.2	(42.6)%	
Others	Operating Profit (Operating Margin)	-0.1 ((26.5)%)	-0.0 ((22.9)%)	+0.0 (+3.6P)	-	
	Net Sales	39.7	39.2	-0.4	(1.1)%	
Total	Operating Profit (Operating Margin)	4.4 (11.3%)	2.0 (5.2%)	-2.4 ((6.0)P)	(54.1)%	

Here are the results by segment.

The following pages will provide more details.

Q1 FY2023: 1					
	Q1	Q1	YoY Com	nparison	
(Billion of yen)	FY2022	FY2023	Changes	(%)	■ Net Sales : Down 2.3 billion yen YoY
Net Sales	19.8	17.4	-2.3	(12.1)%	 UV equipment sales declined YoY owing to final demand slowdown and H2 timing of acceptance inspections Color of UV lamas declined on strue to home demand
Operating Profit	3.9	2.2	-1.6	(42.9)%	 Sales of UV lamps declined on stay-at-home demand for LCD panels running its course and semiconductor market conditions deteriorating Maintenance revenues increased from high operational
Operating Margin	19.8%	12.9%	(7.0)P	-	levels for installed EUV light sources for EUV lithography mask inspections in Q1 FY2022.
Net Sales by Subsegm	nents				
UV Lamps	4.0	3.3	-0.7	(17.8)%	Operating Profit : Down 1.6 billion yen YoY
OA Lamps	1.3	1.3	+0.0	+1.1%	- Earnings decreased because of greater strategic
Optical Equipment Lamps	3.2	2.7	-0.4	(15.2)%	investments in R&D and other activities to drive growth
Light Source Business	8.6	7.4	-1.2	(13.9)%	of EUV light sources and other products
UV Equipment	6.9	5.4	-1.4	(21.7)%	 Profit margins declined owing to lower sales of such high-value-added offerings as UV lamps and UV
Other Optical Equipment	4.3	4.6	+0.3	+7.1%	equipment
Optical Equipment Business	11.2	10.0	-1.1	(10.6)%	

In the industrial process business, both sales and profits declined YoY.

Net sales fell 12.1% to JPY17.4 billion, and operating income declined 42.9% to JPY2.2 billion.

The main reason for the decline in sales is that the semiconductor market, in general, continues to be weak, with a slowdown in final demand for smartphones, PCs, and other products. In addition, semiconductor and LCD panel operations were at a high level until H1 of the previous fiscal year but have been sluggish since then due to deteriorating market conditions.

As a result, sales of UV lamps declined. Sales of large field steppers for cuttingedge IC package substrates were also in a temporary adjustment phase, and in addition, sales for the current fiscal year are biased toward H2, resulting in lower sales in Q1 YoY.

On the other hand, maintenance income from light sources for EUV mask inspection increased due to an increase in maintenance for projects inspected in the previous fiscal year, while operation rates remained at a high level.

Next, the decrease in operating income was due to lower sales, increased development investment for future growth of EUV light source and large field steppers for cutting-edge IC package substrates, and lower sales of high value-added products, such as UV lamps and UV equipment.

Next, I will explain the visual imaging business on slide 10.

	Q1	Q1	YoY Con	nparison						
(Billion of yen)	FY2022	FY2023	Changes	(%)	■Net Sales : Up 2.0 billion yen YoY					
Net Sales	15.5	17.6	+2.0	+13.2%	 Sales increase benefited from progress in SCM reform, easing parts shortages, enabling Ushio to capitalize on replacement demand and boost digital cinema projector 					
Operating Profit	1.2	0.6	-0.5	(48.4)%	revenues - Sales rose on solid demand for events and other activities					
Operating Margin	7.8%	3.5%	(4.2)P	-	general imaging projectors and high-end offerings accounting for greater proportion of revenues - Yen's depreciation contributed to sales gains					
Net Sales by Subsegm	nents									
Projector Lamps	3.4	3.0	-0.3	(10.4)%	Operating Profit : Down 0.5 billion yen YoY					
Illumination Lamps	0.7	0.7	+0.0	+5.9%	- Profit margin deteriorated owing to increase in material					
Light Source Business	4.2	3.8	-0.3	(7.5)%	 easing parts shortages, enabling Ushio to capitalize replacement demand and boost digital cinema proje revenues Sales rose on solid demand for events and other act general imaging projectors and high-end offerings accounting for greater proportion of revenues Yen's depreciation contributed to sales gains 					
Cinema	4.6	6.7	+2.0	+44.7%						
General Imaging	6.7	6.9	+0.2	+4.3%	in human resources and other dreas					
Imaging Equipment	11.3	13.7	+2.3	+20.9%						

In the visual imaging business, both sales and profits increased. Net sales increased 13.2% to JPY17.6 billion, and operating income increased 48.4% to JPY0.6 billion.

The main reasons for the sales increase were as follows. In the digital cinema projector market, SCM reforms are progressing, the impact that parts shortages suffered in the previous fiscal year is easing, and sales have expanded due to replacement demand in movie theaters. In the general imaging field, the percentage of sales of high-end models expanded due to the acquisition of high value-added projects, such as events and amusement parks. In addition, the depreciation of the yen is also having an effect.

On the other hand, operating profit decreased. In addition to increased investment in human resources to build the structure to provide light solutions, the projector of video equipment continued to be affected by the sharp rise in the cost of materials last year, and in Q1, we still handled many products with low profit margins.

The profit margin is also expected to improve, as the soaring cost of parts and materials is expected to subside as the shortage of parts and materials is resolved and will be adjusted in H2.

Next, I will explain the life sciences/photonics solutions businesses on slide 11.

Q1 FY2023:	Life Scier	nces and	Photon	onics Solutions Results			
Life Sciences							
	Q1	Q1	YoY Cor	mparison	Not Sales : Down 0.0 billion von YoY		
(Billion of yen)	FY2022	FY2023	Changes	(%)	INEL Sales . Down 0.0 billion yen 101		
Net Sales	1.4	1.3	-0.0	(4.0)%	- No major business changes		
Operating Profit	-0.6	-0.4	+0.2	_	Operating Profit : Up 0.2 billion yen YoY		
Operating Margin	(47.5)%	(32.7)%	+14.7P	-	 Increase came from concentration and restraint of sales investment due to change in strategy for environmental hygiene solutions. 		
Photonics Solut	ions						
	Q1 (Billion of yen)Q1 FY2022Y0Y Comparison ChangesNet Sales : Down 0.0 billion yen Y0Yales1.41.3-0.0(4.0)%ating Profit-0.6-0.4+0.2-ang Margin(47.5)%(32.7)%+14.7P-(Billion of yen)Q1 FY2022YOY Comparison (13.7)%-Q1 (13.7)%Q1 						
(Billion of yen)	FY2022	FY2023	Changes	(%)	■Net Sales : Up 0.1 billion ven YoY		
Net Sales	2.3	2.5	+0.1	+6.6%			
Operating Profit	0.1	-0.3	-0.4	_	Operating Profit : Down 0.4 billion yen YoY		
Operating Margin	6.1%	(12.9)%	(19.0)P	-	- Increased strategic investments in R&D		
					Copyright $@$ 2023 Ushio Inc. All rights reserved 11		

In the life sciences business, both sales and profits declined. Net sales declined 4% to JPY1.3 billion, and operating income increased JPY0.2 billion to a loss of JPY0.4 billion.

The sales of ultraviolet phototherapy equipment were higher due to the introduction of new products, but the profit decreased mainly due to lower sales of sodium lamps, which are increasingly taken over by solid-state lighting and lamps for environmental hygiene applications, such as Care222.


On the other hand, the improvement in operating income was due to concentration and restraint of sales investment in environmental hygiene products, such as Care222, due to a change in strategy.


Next, in the photonics solutions business, sales increased and profits decreased. Net sales increased 6.6% to JPY2.5 billion, and operating income decreased by JPY0.4 billion to JPY0.3 billion.

The increase in sales was mainly due to increased sales of laser modules for microscopes for R&D applications in universities and companies, while the decrease in profit was mainly due to development expenses for expanding photonics applications and strategic expansion of investment in human resources.

That is all for the explanation of the Q1 financial performance.

Next, I would like to provide details on our full year business forecast. Please refer to slide 13.





Here is a summary of key points regarding the full year forecast for the current fiscal year.

First of all, the full year forecast remains unchanged from that previously announced on May 11. Once again, we would like to explain the main points of our full year forecast.

In this fiscal year, we are expanding strategic investments for future growth and expansion in all of our businesses. As a result, profit growth will be limited relative to sales growth.

In addition, we expect a recovery in business performance from H2 of this fiscal year, with quarterly sales expected to increase from Q2 onward and profit margins to improve toward H2.

This is because sales of UV equipment in the industrial process business are biased toward H2 this year, with 2/3 of the sales volume coming from H2, and the shortage of materials for cinema projectors in the visual imaging business will be resolved over H2 and the soaring costs of materials will also improve.


The status of each segment is explained on the following pages. Please refer to the slide on page 14.

		FY2022 Result	FY2023 Forecast	YoY Cor	nparison	Q1 .	
(Billions	of yen)	FIZUZZ RESUL	FT2025 FORECast	Changes	(%)	progression rate	
let Sales		175.0	188.0	+12.9	+7.4%	20.9%	
Operating Profit*1		15.8	12.5	-3.3	(21.2)%	16.4%	
Operating Margin*1		9.1%	6.6%	(2.4)P	-	-	
EBITDA*2		23.6	21.0	-2.6	(11.2)%	18.9%	
EBITDA Margin		13.5%	11.2%	(2.3)P	-	-	
Ordinary Profit		20.1	14.0	-6.1	(30.5)%	20.2%	
Profit Attributable to Owners of Parent		13.6	10.0	-3.6	(27.0)%	17.9%	
PS (yen)		115.69	90.58	-25.11	(21.7)%	17.0%	
ROE (%) *1		5.7%	4.3%	(1.4)P	-	-	
Annual dividend (yen)		50	50	-	-	-	
orex rate (yen)	USD	135	135	▲0	-	-	
	EUR	141	145	+4	-	-	

Here are the full year forecast figures, but the Q1 progress rate for both sales and profit is low. This was generally in line with the plan, as we had anticipated a slump in the semiconductor market and other factors from the time of the initial plan.

On the next page, a step chart shows the JPY2.6 billion decrease in EBITDA YoY.

Please see the slide on page 15.



There have been no major changes since the announcement of the mediumterm management plan in May, and we are expanding earnings in the visual imaging and life sciences businesses, but we will also increase strategic investments in line with the basic policy of the medium-term management plan, which is to expand our stockpiling for the future. As a result, the Company is expecting a JPY2.6 billion decrease in profit.

	ian of ceases by	Sub-segments				
		FY2022	FY2023	YoY Comparison		
	(Billions of yen)	Results (Reference*1)	Forecast*2	Changes	(%)	
Industrial	Net Sales	88.1	86.0	-2.1	(2.4)%	
Processes	Operating Profit (Operating Margin)	17.2 ^{19.6%}	11.0 12.8%	-6.2 (6.8)P	(36.4)%	
Visual Imaging	Net Sales	67.7	83.5	+15.7	+23.2%	
	Operating Profit (Operating Margin)	3.0 4.5%	4.0 4.8%	+0.9 +0.3P	+32.2%	
Life Sciences	Net Sales	4.6	4.5	-0.1	(3.3)%	
	Operating Profit (Operating Margin)	-4.9 (106.0)%	-2.0 (44.4)%	+2.9 +61.6P	-	
Photonics	Net Sales	10.1	10.5	+0.3	+3.7%	
Solutions	Operating Profit (Operating Margin)	-0.2 (2.9)%	-1.0 (9.5)%	-0.7 (6.6)P	-	
	Net Sales	4.3	3.5	-0.8	(19.4)%	
Others	Operating Profit (Operating Margin)	0.7 17.7%	0.5 14.3%	-0.2 (3.4)P	(34.8)%	
	Net Sales	175.0	188.0	+12.9	+7.4%	
Total	Operating Profit (Operating Margin)	15.8 _{9.1%}	12.5 6.6%	-3.3 (2.4)P	(21.2)%	

This page shows the full year forecasts for each segment.

No major changes have been made since the last announcement in May. I will provide more details on the following pages.

FY2023 F	ull-Yea	r Forec	ast : I	ndustr	ial Proc	esses Business USHIO						
	FY2022 FY2023		YoY Cor	oY Comparison Q1		Business Climate Outlook Whole business seemed to remain unclear confidence						
(Billions of yen)	Results (Reference*)	Forecast	Changes	(%)	Progression rate	- In semiconductor market, capacity utilization adjustments to continue						
Net Sales	88.1	86.0	-2.1	(2.4)%	20.3%	over medium through long terms, investment plan postponements predominate and we will watch the market closely						
Operating Profit	17.2	11.0	-6.2	(36.4)%	20.4%	- In FPD market, capacity utilization should decline on stay-at-home						
Oneveting						Net Sales : Down 2.1 billion yen YoY						
Operating Margin	19.6%	12.8%	(6.8)P	-	-	 Sales of lithography lamps should decrease in reaction to previous year's robust market climate 						
* Each segment fi comparative purp		22 is reference	values that	Ushio prepa	red for	 Sales of UV equipment should remain flat YoY owing to adjustment phase in current fiscal year 						
Comment	•••	-			half of this	 Sales of light sources for EUV mask inspections should drop amid lower light source revenues, notwithstanding higher maintenance revenues fron operation levels staying high 						
fiscal year. - That said, th						Operating Profit : Down 6.2 billion yen YoY						
with the risk Still, we aim expanding d	n to maintain	initial plans	by review	ving our so	chedule for	 Looking to expand strategic investments in R&D to enhance product competitiveness 						
expenses.						- Profitability will probably deteriorate from lower sales of UV lamps						
						Copyright © 2023 Ushio Inc. All rights reserved 17						

In the industrial process business, we plan to decrease sales and profits YoY.

Although progress in Q1 was only 20%, this is in line with the plan, as sales of UV equipment are skewed toward H2 of this year.

The semiconductor market has been sluggish, and although this situation has already been factored into our earnings forecast from the beginning of the fiscal year, there is a possibility that the trend of delayed acceptance inspection for UV equipment due to customers' reasons will further intensify. Although there is no change in the sales volume forecast for the current fiscal year at this time, the risk of future sales being off by a period has increased.

However, even if there is a delay, we intend to maintain the initial plan for profits by reviewing the schedule for development investment and production capacity expansion in line with customers' schedules and by taking firm measures, such as curbing sales promotion expenses.

Product	Latest Status	Sales Transition						
Large Field Stepper for Cutting-edge IC Package Substrates	 While demand in advanced IC package substrates market should expand over medium through long terms, investment plan postponements predominate and we will watch the market closely For further production capacity increase, we will delay the schedule due to market climate change and proceed it step-by-step Investment in development of next-generation lithography equipment (high productivity X high resolution) 	FY21	FY22	FY23 Forecast	FY24 Plan	FY25 Plan		
Direct Imaging Exposure System	 With evolution of IoT and 5G, package market and print circuit boards market are growing steady but currently in an adjustment phase due to slowing demand for final products Sales of high resolution model (2µmL/S) has started and will be contributing to sales after FY2023 Target: latest IC package (Fan-out) and organic package substrates markets 	FY21	FY22	FY23 Forecast	FY24 Plan	FY25 Plan		
EUV Light Source for Mask Inspection	 EUV lithography mask inspection market continues to grow in middle to long terms and high brightness APMI* actual implementation will be after FY2025 Intensifying competitive environment owing to growing cost cutting needs Stepping up efforts to reduce total costs of ownership, strengthening adjustment of Hi-NA implementation in close future and initiating to attract new customers to expand new business opportunities 	FY21		FY23 FY24 orecast Plan	FY25 Plan	Growth potentia		

As for the main products of the industrial process business, as shown on this page, there is no major change from what we explained in the medium-term management plan in May, including sales trends.

As explained earlier, the trend of pushed-back investment in large field steppers for cutting-edge IC package substrates and direct imaging exposure systems is becoming even stronger, so we need to pay attention to changes in the situation going forward.

As for light source for EUV mask inspection, although there is no change from the previous period at this time, we are making efforts to expand new adoption.


FY2023 F	-ull-Yea	r Forec	ast : V	isual :	Imaging	g Business USHIC		
FY2022		ts Frecast	YoY Comparison		Q1	Business environment assumptions		
(Billions of yen) Results (Reference*)	Changes		(%)	Progression rate	Related markets to recover from pandemic, with parts shortages easing			
Net Sales	67.7	83.5	+15.7	+23.2%	21.1%	 Robust demand for digital cinema projectors replacement. Cinema operations to recover in China. In general imaging market, capital investments in events and theme 		
Operating Profit	3.0	4.0	+0.9	+32.2%	15.6%	parks are solid Net Sales: Up 15.7 billion yen YoY		
Operating Margin	4.5%	4.8%	+0.3P	-	-	 Digital cinema projector sales should rise on SCM reform and easing of material shortages and higher replacement demand In general imaging equipment, sales of high-end models should rise on firm demand 		
Each segment fi		22 is reference	values that	Ushio prepa	ared for	 Sales of projector lamps should fall amid transition to solid-state light sources. 		
Comment	on 1Q p	rogressi	on rate	1		Operating profit: Up 0.9 billion yen YoY		
 We anticipal parts and m fully improv We seek to by resolving 	n with project te progress naterials sho ving from 20 enhance pro g parts and r	tions. in SCM refor rtages, with 30. ofit margins naterials sho	rm and a <u>c</u> digital cin in the seco ortages an	pradual res ema proje ond half of d easing t	solution of ector sales f this year :he impact	 While sales of imaging equipment for cinema and other applications should rise, profit margins will probably dwindle owing to deteriorating profit margin of projector lamp (increase in material and parts cost) Looking to expand strategic investments in human resources and other areas to build solutions structure 		
of high cost	s for imagin	g equipmen	t parts and	l materials	S.	Copyright © 2023 Ushio Inc. All rights reserved 19		

The visual imaging business plans to increase both sales and profits YoY.

Market conditions in the cinema and general video business are trending in line with our expectations.

The progression rate in Q1 is low, but this is due to the fact that the shortage of materials related to video equipment, which also affected the previous year's performance, is expected to be resolved by H2, and sales of digital cinema projectors are expected to increase from Q2 onward, which is also on track.

In addition, the profit margin is expected to improve through H2, as the effects of soaring material costs will improve with the progress of SCM reforms and the elimination of material shortages.



I will briefly describe the situation in the main markets of the visual imaging business.

In the cinema segment, the impact of COVID-19 was almost eliminated due to the recovery of the Chinese market. In addition, replacement demand for digital cinema projectors will be in full swing. We expect a 90% increase in sales volume YoY by maximizing the reaping of replacement business through progress in SCM reforms and the elimination of material shortages.

In the general video market, large-scale projection applications for events and theme parks are expected to be strong, and sales of high-end RGB laser projectors, in particular, are expected to increase.


ife Sciences Business						Comment on Q1 progression rate			
	FY2022	FY2023	YoY Comparison		Q1	- Strategic investment and results progressing according to plan			
Billions of yen)	Results (Reference*)	Forecast	Changes	(%) Progression rate		Business environment assumptions			
let Sales	4.6	4.5	-0.1	(3.3)%	30.8%	Moderate demand growth for light-based equipment in medical sector			
						Net Sales: Down 0.1 billion yen YoY			
Operating Profit	-4.9	-2.0	+2.9	-	22.7%	 Sales to decline amid strategy change in environmental hygiene solutions, offsetting higher sales of ultraviolet phototherapy equipment. 			
Operating						Operating profit: Up 2.9 billion yen YoY			
Margin	(106.0)%	(44.4)%	+61.6P	-	-	 Expected to increase by concentration and restraint of sales investment due to change in strategy for environmental hygiene solutions and lower 			
hotonics	Solution	is Busine	222			Inventory write-downs than a year earlier			
	00101010				01	Comment on Q1 progression rate			
	FY2022 Results	FY2023	YoY Com	•	Q1 Progression	- Strategic expansion of R&D investment. Results progressing according to plar			
Billions of yen)	(Reference*)	Forecast	Changes	(%)	rate	Business environment			
Net Sales	10.1	10.5	+0.3	+3.7%	23.9%	Steady growth from shift to solid-state light sources			
ver sales	10.1	10.5	+0.5	+3.7%	23.9%	and enhanced energy efficiency			
Operating	0.2	1.0	0.7		22.404	Net Sales: Up 0.3 billion yen YoY			
Profit	-0.2	-1.0	-0.7	-	32.4%	- Anticipating higher sales of devices and modules (including for medical			
						health, industrial sensors. Operating profit: Down 0.7 billion yen YoY			
Operating	(2.9)%	(9.5)%	(6.6)P						

In the life sciences business, sales is expected to decrease but profit to increase YoY but are in line with the plan at the beginning of the fiscal year.

This year, we expect the loss to be significantly smaller than in the previous fiscal year. This is due to the fact that the inventory valuation loss recorded in Q2 of the previous fiscal year will not occur this fiscal year and that we will review our sales strategy for environmental hygiene products, such as Care222, and concentrate and control sales investment, thereby improving our profits.

Finally, the photonics solutions business plans to increase sales and decrease profits compared to the previous fiscal year, but this business is also performing according to the plan due to strategic expansion of R&D investment.

That's all for the full year forecast by segment.




Finally, I would like to explain about shareholder return.

We plan to pay a dividend of JPY50 per share for FY2023, as planned, in line with our stable dividend policy.

In addition, as part of the midterm management plan announced on May 11, the Company released and is proceeding with the purchase of up to a total of JPY30 billion of its own shares as part of a drastic capital efficiency improvement program. As of the end of July, the purchase amount reached JPY7 billion, and the progress rate was approximately 24%, showing steady progress in purchases. For more information, please see the press release on August 2.


This is the end of my presentation.




(New) Business Segments and Main Products


New Business **Main Products Product Examples** Segment Light Source: UV lamps, OA lamps, Optical equipment lamps, etc. 18 R Industrial Equipment: UV Equipment, Curing equipment, EUV light source for mast inspection, Maintenance Processes Direct imaging lithography equipment EUV light source for EUV mask inspection UV lamps Large filed OA lamps steppers service etc. Light Source: Cinema lamps, Data projector lamps, etc. Equipment: Digital cinema projectors, projectors for general imaging, Peripheral equipment, Maintenance, etc. 110 Visual Imaging Cinema lamps Data projector lamps Digital cinema projector Projectors for general imaging Peripheral LED wall equipment display Light Source: Care222 related 5 products Equipment: UV curing 11 AL. Life Sciences Excimer light Disinfection and virus inactivation solution "Care222" phototherapy device "TheraBeam series" equipment, etc. Light Source: Solid-state light sources (Laser Diode/LED) Photonics Solid-state light sources (LD/LED) Solutions Laser module Copyright © 2023 Ushio Inc. All rights reserved 24


USHIO




Old business segments				S			
Reporting Segments	Subsegments			Subsegments	Reporting segments		
	Liplagan	•OA		● UV lamps			
	Halogen lamps	Illumination		• OA lamps	Light Source Business	Industrial Processes	
		Others		• Optical equipment lamps			
ight Source	Discharge lamps	UV lamps			Optical Equipment		
Business		Cinema lamps		 UV equipment 			
		 Data projector lamps 		 Optical equipment 	Business		
		Optical Equipment lamps		Projector lamps		– Visual Imaging	
		 Others 			Light Source Business		
	Solid state	light sources		Illumination lamps			
Optical	 UV equipn 	nent	/// ,	 Cinema projectors 	Imaging		
Equipment Business	Cure equip	oment		• Genera imaging projectors	Equipment Business		
Dusiness	Others		\square	• Life sciences products	Light Source	Life Sciences	
Imaging	● Cinema		r X/~		Optical Equipment	Life Sciences	
Equipment Business	General in	naging		• Solid state light sources	Light Source Business	Photonics Solutions	
Dusiness	 Lighting equipment, etc. 		$\gamma \rightarrow$	• Others	Optical Equipment	Others	
Others	Machinery	for industrial use and others	<u> </u>	• Others	Business	Utners	









(Billions of yen)			FY202	FY2023	YoY Comparison			
		1 Q	2 Q	3 Q	4 Q	1 Q	Changes	(%)
Net Sales		39.7	48.2	40.4	46.6	39.2	-0.4	(1.1)%
Operating Profit*1		4.4	5.6	3.4	2.3	2.0	-2.4	(54.1)%
Operating Marg	jin∗1	11.3%	11.7%	8.5%	5.0%	5.2%	(6.0)P	-
EBITDA*2		6.3	7.6	5.3	4.3	3.9	-2.3	(37.4)%
EBITDA Margin		15.9%	15.8%	13.2%	9.4%	10.1%	(5.8)P	-
Ordinary Profit		6.2	7.3	4.3	2.1	2.8	-3.4	(55.1)%
Profit Attributable Owners of Parent	to	3.8	5.6	2.5	1.6	1.7	-2.0	(53.5)%
EPS (yen)		32.18	47.87	21.80	13.78	15.36	-16.82	(52.3)%
FOREX (yen)	USD	126	137	144	133	136	+10	-
I OKEA (yell)	EUR	137	140	144	143	148	+11	-


${\tt Copyright} @ {\tt 2023} {\tt Ushio} {\tt Inc. All rights reserved} \qquad {\tt 31} \\$


*1. FY2022 segment figures are reference values that Ushio prepared for comparative purposes
 *2. FY2023 operating profit target excludes new goodwill amortization.


31


		FY2022	FY2023	YoY Con	parison	
	(Billions of yen)	Q1	Q1	Changes	(%)	
	Net Sales	19.8	17.4	-2.3	(12.1)%	
Industrial Processes	Operating profit	3.9	2.2	-1.6	(42.9)%	
	Operating Margin	19.8%	12.9%	(7.0)P	-	
	Net Sales	15.5	17.6	+2.0	+13.2%	
Visual Imaging	Operating profit	1.2	0.6	-0.5	(48.4)%	
Integrity	Operating Margin	7.8%	3.5%	(4.2)P	-	
Life Sciences	Net Sales	1.4	1.3	-0.0	(4.0)%	
	Operating profit	-0.6	-0.4	+0.2	-	
	Operating Margin	(47.5)%	(32.7)%	+14.7P	-	
Photonics Solutions	Net Sales	2.3	2.5	+0.1	+6.6%	
	Operating profit	0.1	-0.3	-0.4	-	
Conactorio	Operating Margin	6.1%	(12.9)%	(19.0)P	-	
	Net Sales	0.4	0.2	-0.2	(42.6)%	
Others	Operating profit	-0.1	-0.0	+0.0	-	
	Operating Margin	(26.5)%	(22.9)%	+3.6P	-	
	Net Sales	39.7	39.2	-0.4	(1.1)%	
Total	Operating profit	4.4	2.0	-2.4	(54.1)%	
	Operating Margin	11.3%	5.2%	(6.0)P	-	l rights reserved 32

USHIO Cash Allocation Strategy Strategy from FY2023 through FY2025: Endeavor to enhance capital efficiency through in-house stock investment and major growth investment allocations Cash generation Cash inflows Cash outflows • Operating cash flow under medium-term management plan: ¥60 billion over three years Asset sales: ¥15~¥20 billion • Interest-bearing debt usages: ¥40 billion+ a (Lower cost of capital) Strategic investments Interest-bearing debt ¥40 billion+ ¥40 billion+ **Capital allocations** • Strategic investments: ¥40 billion+ Growth investments (including M&A): ¥40 billion+ Asset sales ¥15~¥20 billion Financial position Equity ratio: At least 60% In-house stock investment + In-house stock investment + dividends ¥70~90 billion Stable dividends Undertake in-house stock investment, factoring in business performance and financial position (Resolved to set aside 30 billion yen for share repurchases in the first year) dividends: Around ¥70-¥90 billion Operating cash flow under medium-term management plan ¥60 billion over three years Target ROE of at least 8% by FY2025 Copyright © 2023 Ushio Inc. All rights reserved 33










ilossary		USHIC
AI	Artificial Intelligence	
APMI	Actinic Patterned Mask Defect Inspection	
BGA	Ball Grid Array	
CoO	Cost of Ownership	
CPU	Central Processing Unite	
DCP	Digital Cinema Projector	
DI	Direct Imaging	
EUV	Extreme Ultraviolet Radiation	
FPD	Flat Panel Display	
GPU	Graphic Processing Unit	
ΙοΤ	Internet of Things	
OA	Office Automation	
TNO	The Netherlands Organization of Applied Scientific Research	
UV	Ultraviolet	
5G	5 th Generation	



USHIO

<Disclaimer>

This report contains forward-looking statements, including earnings forecasts, which are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Please be advised that actual results may differ substantially from those forward-looking statements due to various factors.

 ${\tt Copyright} @ 2023 {\tt Ushio Inc. All rights reserved} \qquad 40$



Contact: Investor Relations Section Corporate Communication Department Ushio Inc. Email: <u>ir@ushio.co.jp</u> https://www.ushio.co.jp/en/

 ${\tt Copyright} \, {\tt @} \, {\tt 2023} \, {\tt Ushio} \, {\tt Inc.} \, {\tt All} \, {\tt rights} \, {\tt reserved} \qquad {\tt 41}$